Article
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Pharmacological research - 1 May 2023
Xu Cong, Jiang Ze-Bo, Shao Le, Zhao Zi-Ming, Fan Xing-Xing, Sui Xinbing, Yu Li-Li, Wang Xuan-Run, Zhang Ruo-Nan, Wang Wen-Jun, Xie Ya-Jia, Zhang Yi-Zhong, Nie Xiao-Wen, Xie Chun, Huang Ju-Min, Wang Jing, Wang Jue, Leung Elaine Lai-Han, Wu Qi-Biao
Abstract excerpt
Nearly half of all Asian non-small cell lung cancer (NSCLC) patients harbour epidermal growth factor receptor (EGFR) mutations, and first-generation EGFR tyrosine kinase inhibitors (TKIs) are one of the first-line treatments that have improved the outcomes of these patients. Unfortunately, 20% of these patients can not benefit from the treatment. The basis of this primary resistance is poorly understood....
Topics
Join the communities discussing this publication.